| Useful Articles |
Hubs | Hubbers | Topics | Request |
| #1 in Business | Subscribe Email Print |
|
You are here: Home > Finance > Loans > Invoicing Methods Can Effect The Ability To Factor |
|
Useful Articles - Invoicing Methods Can Effect The Ability To Factor
If you are considering using accounts receivable factoring as a financing tool, you should carefully consi According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product der the type of billing arrangement you have with your customers. Invoice factoring relies on important c ; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug. Examples of combination products may in onsiderations concerning your business model that could make it easier to get funding. When you initially lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together. set up your agreement with the customer, you should specifically outline the work to create deliverables o here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe r milestones that allow you to invoice. By setting these milestones, the customer is obligated to pay for d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations. Combination pro the work to that point and you can generate an invoice for that part of the goods or services. Contrast ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc this scenario to progress billings, an arrangement in which the customer advances money for the job as a w easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi hole. The factor is hesitant to advance funds to the client with progress billings, since the company get nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically ing billed may become unhappy along the way and stop making payments. With milestones, on the other hand, and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ that is not a problem. Pre-billing for services is another example of a problem for factoring invoices. ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi Common to the publishing and advertising industries, the customer is invoiced for invoiced for a publicati ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it. Following aspects would a on that will run in the future. From a factoring standpoint, proceeds of the obligation are assigned to a dd to the challenges in developing combination products: Which markets to tap where the combination products can do fairly well? Which combination prod third party. If the work has not been satisfactorily completed, the customer likely will not pay the ent cts are meaningful and rational? Which therapeutic categories to select? Which Combinations can address unmet needs of the patients? Do combin re amount, if at all because there are too many "outs". The factoring company has advanced a significant tions increase the patient compliance? What would be the developing cost? How to tackle the risks encountered during combination product developmen amount of funds up front, so they are left holding the bag when the customer refuses to pay. In this situ t? As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel tion, the factoring company will almost assuredly adopt recourse factoring. This means that if the custom ping new procedures for reviewing their safety, efficacy and quality. Professional from academic institutions, pharmaceutical industries, health care indust er doesn't pay the client the full amount that was invoiced, the factoring company can collect the money t y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products hat was advanced. Even if you don't need to . As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de >factor your invoices, it is usually better to structure your invoicing in such a way that the custome elopment. They need to be wiser in analyzing the market trends and the regulatory requirements. Companies that provide selfless information through particip r is obligated to pay during each step. The milestone arrangement is the best way to accomplish this goal tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products
HTTP = HTML link (for blogs, profiles,phorums):
Related Articles:Federal Trade Commission Budget FY 2007 Credit Card Services And Why We Need Those Little Cards
|